LAVA Therapeutics N.V.

At LAVA, we are focused on applying our expertise in gamma-delta T-cell engagers (TCEs) to transform cancer therapy. We refer to our compounds as gamma-delta bispecific T-cell engagers, or gamma-delta bsTCEs. Our platform generates therapeutics that specifically activate a unique and relatively abundant effector gamma-delta T-cell subset called Vγ9Vδ2 (Vgamma9-Vdelta2) T-cells that have the ability to trigger activity of immune cells of both the innate and adaptive immune system. Our gamma-delta bsTCEs have demonstrated superior efficacy and safety profiles compared to other bsTCE approaches in preclinical studies and show preferential activity against tumor cells thereby potentially limiting toxicity in healthy tissue. To date, we are the only company developing bispecific gamma-delta T-cell engaging antibodies for the treatment of cancer. We are building a pipeline of gamma-delta bsTCEs that have applications in both solid and hematologic malignancies. Our lead program, LAVA-051, targets the tumor specific antigen CD1d, which can be overexpressed in multiple myeloma, chronic lymphocytic leukemia (CLL), and acute myeloid leukemia (AML), among other tumor types. LAVA-051 will enter a Phase I/IIa study in 1Q21.

Sanbio B.V.

As an independent distributor and manufacturer of life science products and services for research and diagnostics, we strive to build long-term relationships with both our clients and suppliers. In accomplishing our mission, it is our experience that knowledge makes the difference. Sanbio is part of Europa Biosite, a European supplier of life science products and services. We are a group of six leading distribution companies: Biomol in Germany, Cambridge Bioscience in the UK and Ireland, LubioScience in Switzerland, Nordic BioSite in the Nordics and Baltics, Sanbio in Benelux and Szabo-Scandic in Austria. The group has a portfolio of over 5 million products, representation in 15 European countries and a highly skilled team of over 150 employees.

Biotech Booster

Biotech Booster is a national program to support commercialization of biotechnology findings. The Biotech Booster program offers mentorship, financial support and networking opportunities, to guide founders from the idea stage to developing an investable/commercial proposition.

Hycult Biotech

Hycult Biotech is a manufacturer of research reagents in the field of innate immunity. Our products are co-developed with researchers around the globe. By connecting science with disease, these products offer innovative research solutions that enable better treatment, monitoring and prevention. Our focus on innate immunity means we pay special attention to products relating to antimicrobial peptides, complement, acute phase proteins, LPS and microbial toxins. Hycult Biotech further has a specific interest in inflammation and cell - and tissue damage. We contribute to these areas with our extensive knowledge in the development and production of assays, antibodies and proteins. We believe a better treatment starts with an enhanced disease understanding and we are devoted to offer research – and diagnostic tools that assist in the translation of these insights.

inbiome

By combining machine learning with advanced chemistry, inBiome enables microbiology labs around the world to rapidly and easily identify bacteria in a wide range of clinical sample types, including complex microbiota. Even uncultivable and antibiotic-treated species are detected. Current applications include replacing traditional culture in ICUs for more accurate, same-day results, infection control, gut flora analysis, and various r&d applications for healthcare, pharmacy, and food industries. Promising new applications currently undergoing clinical trials include IBD and Sepsis diagnostics and preventive screening.